Skip to main content

Cancer: Drugs

Volume 508: debated on Wednesday 24 March 2010

To ask the Secretary of State for Health pursuant to the answer of 16 March 2010, Official Report, column 765WA, on cancer drugs, which of the patient access schemes considered by the National Institute for Health and Clinical Excellence (a) were and (b) were not implemented. (323833)

Where a patient access scheme is proposed by a manufacturer, and approved by the Department, in the context of a National Institute of Health and Clinical Excellence (NICE) appraisal, it must be available for local implementation when NICE recommends, or partially recommends, the use of the drug in question.